Research view
Switch to patient viewProstate cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target or a country to narrow the list.
- All targets
- PSMA 273
- AR 16
- TP53 2
- PARP 13
- PTEN 4
- AKT 1
- BRCA2 7
- BRCA1 9
- PI3K 2
- STAT3 0
- PD-L1 6
- mTOR 1
- PD-1 13
- EZH2 7
- MYC 1
- B7-H3 8
- EGFR 2
- CTNNB1 1
- JNK 0
- ERK 0
- HIF-1 0
- VEGF 2
- BCL-2 0
- AMPK 0
- CDK4/6 4
- HER2 6
- MAPK 0
- NRF2 0
- FAK 0
- YAP 0
- PPAR 0
- IL-6 0
- STING 0
- COX-2 0
- CTLA-4 0
- DLL3 6
- GLP-1 1
- GPX4 0
- HSP90 0
- ATM 1
- HDAC 0
- IL-15 4
- METTL3 1
- BRD4 0
- HER3 2
- JAK 1
- CXCR4 0
- TROP2 3
- CD47 1
- IGF1R 0
- IL-1 0
- MET 1
- PALB2 4
- RB1 0
- TNF 0
- APOE 0
- FGFR 1
- KRAS 0
- MDM2 0
- MEK 0
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF
Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
5 of 32 running projects, newest first. Listed amounts together: €116.1m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
No trial in this view states that it shares participant data.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 42
- Organoids 15
- Mendelian Randomization Analysis 38
- CRISPR-Cas Systems 14
- Gene Expression Profiling 153
- Sequence Analysis, RNA 11
- Whole Genome Sequencing 9
- Exome Sequencing 4
- Proteomics 47
- Metabolomics 27
- Mass Spectrometry 16
- Flow Cytometry 58
- Immunohistochemistry 120
- Liquid Biopsy 30
- Circulating Tumor DNA 32
- Xenograft Model Antitumor Assays 287
- Positron-Emission Tomography 125
- Magnetic Resonance Imaging 464
- Machine Learning 122
- Deep Learning 101
- Cohort Studies 276
- Genome-Wide Association Study 61
Protocol for generating and characterizing Matrigel-free prostate cancer patient-derived organoids.
Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review.
Unmasking prostate cancer risk factors leveraging organoid technology.
Generation of a Mouse Prostate Organoid-Based Model for Studying Host-Pathogen Interactions.
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.